| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4336.0 | 4516.6 | 3941.9 |
| Other income | 54.5 | 52.5 | 79.7 |
| Total income | 4390.5 | 4569.1 | 4021.6 |
| Profit before exceptional items & tax | 141.1 | 327.9 | 114.1 |
| Exceptional items | -13.5 | -80.4 | -17.2 |
| Profit before tax | 127.6 | 247.5 | 96.9 |
| Net profit | 136.8 | 198.6 | 89.2 |
| Operating margin | 2.9% | 5.4% | 2.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +53.40% |
|---|---|
| Net profit, quarter on quarter | -31.10% |
| Revenue, year on year | +10.00% |
| Operating profit, year on year | +151.70% |
| Operating profit, quarter on quarter | -68.60% |
NSE results filing, NSE: BIOCON. Figures extracted from the filing.
Biocon Ltd: key numbers
- Share price
- ₹382.15
- Market cap
- ₹62,279 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 125.7×Sector 50.4×
- Promoter holding
- 44.68%-0.23% QoQ
- FII holding
- 8.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon Bags New Order from Bahiafarma and Bionovis
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
- From
- Bahiafarma and Bionovis (Brazil PDP program)
- Execution
- 10 years
Biocon Investor Presentation: Key Takeaways
Biocon Q1 FY27 revenue grew 10% YoY to INR 3,433 Cr. Biopharmaceuticals grew 17% while Services declined 16%. Group EBITDA was INR 902 Cr (21% margin) and Net Profit jumped 245% to INR 145 Cr.
Biocon Investor Presentation: Key Takeaways
Biocon reported Q1 FY27 revenue of ₹4,336 Cr (up 10% YoY) and Net Profit (before exceptional) of ₹145 Cr (up 245% YoY). Strategy focuses on North American biosimilar launches and generic margin expansion.
Biocon Earnings Call: Key Takeaways
Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.
Biocon Earnings Call: Key Takeaways
Biocon Q4 FY26 reported 10% YoY revenue growth (ex-lenalidomide) with integration of biosimilars/generics complete. Focus shifts to execution and deleveraging.